To qualify for Wegovy for CV risk reduction, you typically need: Established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), BMI 27 kg/m , and documentation of ongoing lifestyle modifications
Fourth, although STEP-8 provides the only head-to-head randomized evidence directly comparing semaglutide and liraglutide, its trial population may not fully reflect the demographic and clinical profile of Greek patients with obesity
If youre considering a low-carb approach, or wondering how it fits with a GLP-1 medication, our team in Houston, Katy, and Webster can help you build a plan thats both effective and safe
Nutrient intake often drops, too
Cortisol can delay or disrupt your period, especially in the first few months of treatment
In practice, this modification means IGF-1 LR3 circulates longer and produces a more systemic effect than native IGF-1, which is quickly bound and neutralized once released into circulation